Medical Psilocybin Propagation Committee Meeting Minutes

Location: Virtual

Date: January 21, 2026

Time: 3:00 pm to 5:00 pm

Minute Taker: Adrian Estrada

**This meeting was recorded. For specific details pertaining to the meeting, please refer to the recording located on the Medical Psilocybin Advisory Board Website: Psilocybin Advisory Board*

Agenda Items

1. Call to Order and Opening Statements
    - DOH staff introduced Chair Chris Peskuski
    - Chair welcomed participants and acknowledged veteran status and personal relationship to the medicine
    - Meeting opened with 30 seconds of silence recognizing global events
    - Chair outlined expectations for introduction and participation

2. Introductions

Participants introduced themselves verbally or via chat and shared background, experience, and affiliations. Introductions included New Mexico residents, cultivators, mycologists, researchers, therapists, software developers, and public participants. Several participants noted no organizational affiliation.

3. Review of Agenda
    - Agenda reviewed
    - No objections noted

4. Documentation Routing
    - DOH clarified how meeting documents, outlines, and drafts would be posted
    - Participants were informed documents are starting points and subject to revision
    - Transparency and public review emphasized

5. Lessons Learned and Discussion

Tori Armbrust and Colorado Experience

- Discussion referenced lessons learned from Colorado and Oregon programs

- Participants discussed balancing safety, access, and economic feasibility

Cultivation and Environmental Controls

- Discussion held on CO2 monitoring, fresh air exchange (FAE), air circulation, and environmental controls
- Participants shared differing views on necessity and cost of CO2 monitoring
- Clarification provided that cultivation approaches vary, including in-vitro methods
- Discussion included fungal gnats, contamination mitigation, and organic remediation options

Pesticides, Fungicides, and Contamination

- Discussion held on whether fungicides should be permitted and if testing would be required
- Participants noted existing standards for consumable mushrooms
- Emphasis placed on contamination testing, including molds and pathogens
- Hydrogen peroxide referenced as an organic compliant mitigation option

Harvesting, Processing, and Homogenization

- Discussion held on harvesting practices, processing, batch definition, and homogenization
- Concerns raised about whole fruit distribution and consistency
- Participants discussed potency degradation risks during homogenization
- Powderization discussed as increasing hydrophilicity and consistency

Testing and Quality Assurance

- Discussions included potency testing, homogeneity testing, heavy metals, alkaloid reporting, and retesting intervals
- Recommendation made to define a core set of alkaloids for reporting
- Participants discussed testing costs and economic feasibility
- DOH clarified that labs must develop SOPs and meet accreditation requirements
- Clarified that psilocybin products cannot cross state lines

Batch Size, Scale, and Market Demand

- Discussion held on batch size flexibility and scalability
- Participants emphasized need to accommodate both small and large operations
- Market demand and patient access discussed as factors influencing regulation
- Overregulation concerns raised

Permitting Structure

- DOH clarified permitting structure for cultivation, harvesting, processing, and production
- One permit model discussed with flexibility for applicable activities
- DOH confirmed no permit fee at this time
- Discussion held on whether caps on number of permits should exist

Sunset Clause and Residency

- Discussion held on sunset clauses and residency requirements
- Oregon model referenced, including residency duration and ownership thresholds
- DOH advised participants to bring draft language for future discussion

6. DOH Provided Outline Review

    - DOH reviewed outline including purpose, scope, authorized species, permit structure, zoning, agricultural standards, environmental controls, harvesting, processing, batch definition, and testing
    - Participants encouraged to review and submit feedback

7. USDA Mushroom Good Agricultural Practices (MGAP)
    - USDA GAP standards referenced as a potential resource
    - Chair shared USDA Mushroom GAP link in chat

8. Proposals
    - Chair requested plain language proposals
    - Participants encouraged to submit research, studies, and draft language
    - Chair emphasized proposals will not be implemented immediately but reviewed and refined

9. Other Business and Discussion
    - Participants discussed future tracking models and whether cannabis-style tracking would apply
    - Chair indicated cultivation remains a substantial area for future work
    - DOH confirmed submissions may be documents or hyperlinks with context
    - Written public comments must include full legal name and affiliations

10. Next Meetings
    - January 30, 2026, 3:00 pm to 5:00 pm
    - February 4, 2026, 3:00 pm to 5:00 pm
    - February 11, 2026, 3:00 pm to 5:00 pm

Written Public Comment

- Submit to medical.psilocybin@doh.nm.gov
- Include full legal name and organizational affiliations
- If referencing external sources, provide working hyperlinks only
- Deadline for this meeting's record: January 22, 2026, at 5:00 pm

11. Adjournment
    - Meeting adjourned at approximately 4:41 pm

Attendance

Chair

Chris Peskuski

DOH Staff

Adrian Estrada, DOH
Jonathan Mouchet, DOH
Dominick Zurlo, DOH
Ismail Zoutat, DOH
Cathy Augeri, DOH
Jorge Gonzales, DOH
Brenda Martinez, DOH
Raymond Gallegos, DOH
Robert Truckner, DOH

Participants and Public Attendees

Gregory Evans
Ben Edwards
Bo Farley
Brett Phelps
Eric Barlow
James Hosobe
Erik Baca
Scott Folkman
Michael McDowell
James Ferreira, Ignite Synergy
Manuel Griego
Alan Thomas
Estevan Hernandez
Jon Eslick

Tori Armbrust
Taye Davis
Marcus Ryals
Sarah Lopez
Ash Shelton
Matthew Armstrong (Inday Animosh)
Dan Jennings
Des Garcia
Shane McDaniel
Francesca Banci
Don Moser

Comments submitted by email

1. Hey Chris,

This is a quick video from one of the most trusted Mushroom cultivation supply companies that explains strains, potency and the different chemical compounds found in Psylocibin. Thought you might be interested.

https://www.youtube.com/watch?v=-aNOq9u_8Lc

Thanks for all you are doing!!
Shane McDaniel
shmcdaniel@msn.com

2.

Facility Licensing Consideration

*** I, Gregory Evans, am making this proposition for committee discussion and consideration. I am an independent researcher with no affiliations.

Given the rapid deadline for cultivation and testing standards, and the goal of standing up production capacity quickly, the committee may wish to consider whether existing agricultural

infrastructure could accelerate program readiness through temporary or other licensure platforms. Alternatively, would a small-scale independent approach be more applicable to the iterative scale of the program rollout process?

Core Question to propose to the committee:

Should the program provide licensure pathways for facilities currently producing agricultural (food) or functional mushrooms to simultaneously cultivate psilocybin-containing species? If so, what additional requirements and protocols would be necessary?

Sub-Questions for Committee Discussion

1. Considerations around Segregation & Quarantine

- What physical and operational separation would be required, if any, between food-grade and controlled substance production areas?
- Should this mirror MGAP's existing separation requirements for unpasteurized substrate handling, or require stricter standards?

2. Product Integrity & Traceability

- What chain-of-custody documentation would our regulating body need to require to mitigate instances of cross-contamination or product mix-up between food and psilocybin crops?
- Can existing MGAP traceability frameworks be extended, or is a parallel system required for controlled substances?
- Does this pose an FDA concern or risk?

3. Risk Assessment - Biological

- Are there credible contamination or cross-pollination concerns between genus/species cultivated in shared environments?
- What contamination vectors (substrate, spawn, air handling) require specific mitigation protocols?
    - *Note that this is not an effort to control substrate or cultivation techniques, but specifically to consider the interactions of space. For example, if air moves from one room to the next and carries spores that could potentially impact that facility's other spaces where FDA regulations may take precedence.*
- OPEN for input here.

4. Scaling & Program Stand-Up Options

- Is licensing existing MGAP-certified facilities the fastest pathway to operational supply?
- Alternatively, would small-scale or home cultivation licensing better serve immediate program needs while full-scale facility standards are developed?
- *What licensing models beyond these two options could we explore?*
- What further analysis may be needed before formalizing recommendations?

5. Licensing Structure (Exploratory)

- Should the committee consider whether facility licensing and cultivator credentialing could function independently - for example, a licensed facility with a separately credentialed operator?
- What are the tradeoffs of such a structure for accountability, liability, and speed of program implementation?

6. Industry & Facility Risk Considerations

- What mitigating risks could dual-use licensing trigger for facilities, the broader mushroom industry, or the program itself?
- Could engaging in psilocybin production create reciprocal harm for a facility's existing food/functional operations (e.g., insurance, market access, federal scrutiny, certification status)?
- What lasting impacts - positive or negative - should the committee anticipate for facilities that participate in dual-use production?

Closing Note

This document is submitted for committee discussion only. It does not represent a formal recommendation. Feedback and alternative approaches are welcomed.

Document prepared by Gregory Evans | Exported: 26 January 2026 |
gregory.l.evans@gmail.com